To determine the effect of each dose of avosentan on time to doubling of serum creatinine, end stage renal disease (ESRD) or death when administered on top of standard treatment in subjects with type 2 diabetes mellitus and diabetic nephropathy.
To determine the effect of each dose of avosentan on: cardiovascular mortality
(and 5 more...)
21 Years to 80 Years (Adult, Senior)
July 15, 2005
October 5, 2007
Dr. Mark Warren Greenville, North Carolina, United States
† Study has passed its completion date and status has not been verified in more than two years.